On February 24, 2026, Novo Nordisk announced it will cut the list price of Wegovy, Ozempic, and Rybelsus to $675/month effective January 1, 2027. That's roughly 50% off Wegovy's current $1,349 list price and 35% off Ozempic. Sounds transformative — but the details matter.
What's Actually Changing
The list price (also called WAC — Wholesale Acquisition Cost) is the sticker price manufacturers set for their drugs. It's what pharmacies pay wholesalers, and it determines what patients with percentage-based coinsurance or high-deductible plans pay out-of-pocket. Dropping the list price from $1,349 to $675 directly benefits these patients.
Who Benefits
| Patient Type | Current Cost | After Jan 2027 | Savings | Impact |
|---|---|---|---|---|
| High-deductible plan (coinsurance) | $270-405/mo (20-30%) | $135-203/mo | $135-202/mo | ✅ Major |
| Plan with fixed copay | $25-75/mo | $25-75/mo | None | ❌ No change |
| NovoCare self-pay | $199-399/mo | $199-399/mo | None | ❌ No change |
| TrumpRx pricing | ~$350/mo | ~$350/mo or lower | Possible | ⚠️ TBD |
| Medicare Part D (Bridge) | $50/mo | $50/mo | None | ❌ No change |
| Uninsured (retail) | $1,349/mo | $675/mo | $674/mo | ✅ Major |
| Compounded users | $99-249/mo | $99-249/mo | N/A | ❌ No change |
Who Doesn't Benefit
Self-pay patients through NovoCare — no change. Your price is already set below the new list price.
Patients with fixed copays — if your insurance charges a flat $50 copay regardless of the drug's list price, the cut doesn't change your out-of-pocket cost.
Compounded GLP-1 users — the list price of brand-name Wegovy has no bearing on compounded semaglutide pricing. GobyMeds stays at $99, Oak Longevity at $130, etc.
Medicare Bridge participants — the $50/month copay is set by the Bridge program, not by list price.
What This Means for the GLP-1 Market
The price war continues
Novo's move is partly competitive. Eli Lilly's Foundayo launched at $149-299/month. Compounded providers offer semaglutide at $99-249. The $1,349 list price was increasingly untenable as alternatives proliferated. At $675, Wegovy's list price is still roughly 3x higher than self-pay programs and 7x higher than GobyMeds — but it's moving in the right direction.
The compounding crackdown incentive
Lower brand-name pricing weakens the economic argument for compounded GLP-1s. If regulators can point to $675 (or $199-349 self-pay) options as "affordable alternatives," the case for allowing compounding becomes harder to make. This price cut may accelerate the FDA's crackdown timeline.
2027 and beyond
The January 2027 timing isn't coincidental — it aligns with Medicare Maximum Fair Price negotiations under the Inflation Reduction Act and the transition from the GLP-1 Bridge to the BALANCE Model. Novo is positioning Wegovy's pricing for the next era of government-negotiated drug costs.